IDV vehicle
36E79724D0001
NEW AWARD FOR RANIBIZUMAB (LUCENTIS) SYRINGES WITH GENENTECH USA, INC. PERIOD OF PERFORMANCE IS 12/23/23 TO 12/22/24 WITH FOUR ONE-YEAR OPTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Veterans Affairs |
| Office | NAC PHARMACEUTICALS (36E797) |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $3.0M |
| Start date | Dec 23, 2023 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Sep 1, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 13 of 13 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 1, 2026 | P00013 | $0 | IMPLEMENTING EO 14398 DEI DISCRIMINATION |
| Jun 22, 2026 | P00011 | $0 | AUTHORIZE CREDITS AND REBILLS DUE TO DATABASE PRICING ERROR. |
| Dec 17, 2025 | P00010 | $0 | INCORPORATE GENENTECH'S 2026 SUBK PLAN INTO CONTRACT. PLAN EFFECTIVE 1/1/2026 - 12/31/2026. |
| Nov 26, 2025 | P00009 | $0 | EXERCISE THE SECOND OPTION YEAR FOR RANIBIZUMAB (LUCENTIS) SYRINGES CONTRACT 36E79724D0001 WITH GENENTECH USA, INC. WITH PRICE CHANGES. |
| Nov 25, 2025 | P00008 | $0 | INCORPORATION OF THE 2026 FEDERAL CEILING PRICES WITH GENENTECH CONTRACT 36E79724D0001 WITH PRICE ADJUSTMENTS. |
| Dec 20, 2024 | P00007 | $0 | INCORPORATE GENENTECH'S 2025 SUBK PLAN INTO CONTRACT. PLAN EFFECTIVE 1/1/2025 - 12/31/2025. |
| Dec 5, 2024 | P00006 | $0 | INCORPORATION OF THE 2025 FEDERAL CEILING PRICES WITH GENENTECH CONTRACT 36E79724D0001 WITH PRICE ADJUSTMENTS. |
| Nov 25, 2024 | P00005 | $0 | EXERCISE THE FIRST OPTION YEAR FOR RANIBIZUMAB (LUCENTIS) SYRINGES CONTRACT 36E79724D0001 WITH GENENTECH USA, INC. WITH NO PRICE CHANGES. |
| Feb 21, 2024 | P00003 | $0 | UPDATE TO COST RECOVERY FEE (CRF) AND SUBMISSION OF QUARTERLY SALES REPORTS 36E79724D0001, GENENTECH USA, INC. FOR RANIBIZUMAB (LUCENTIS) SYRINGES. |
| Feb 21, 2024 | P00004 | $0 | INCORPORATE GENENTECH'S CORRECTED 2024 SUBK PLAN INTO CONTRACT. PLAN EFFECTIVE 1/1/2024 - 12/31/2024. |
| Dec 7, 2023 | P00002 | $0 | INCORPORATION OF 2024 FEDERAL CEILING PRICE INTO CONTRACT. THE AWARDED NATIONAL CONTRACT PRICE REMAINS UNCHANGED. |
| Dec 5, 2023 | P00001 | $0 | INCORPORATE THE APPROVED 2024 COMMERCIAL COMPANY WIDE SUBCONTRACTING PLAN FOR GENENTECH USA, INC. FOR THE PERIOD OF 1/1/24 TO 12/31/24. |
| Oct 23, 2023 | 0 | $0 | NEW AWARD FOR RANIBIZUMAB (LUCENTIS) SYRINGES WITH GENENTECH USA, INC. PERIOD OF PERFORMANCE IS 12/23/23 TO 12/22/24 WITH FOUR ONE-YEAR OPTIONS. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.